News | September 17, 2024
Wacker collaborates with MinervaX for prophylactic vaccine targeting Group B streptococcus
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Dr. Bunker will focus on leading Research and Development (R&D) in San Diego, advancing the preclinical pipeline and optimizing the Company’s Integrated Discovery Engine.
Coordinated by the Medical University of Vienna, a consortium of 13 leading European organizations including university hospitals, research institutions and healthcare companies will conduct the 5-year project co-funded by Horizon Europe.
The hybrid congress will take place from 1-4 June in Copenhagen, as well as virtually
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
WHO’s post EUA inspection found deficiencies in Good Manufacturing Practice at the facility
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
